Page last updated: 2024-08-17

alloxan and bms 536924

alloxan has been researched along with bms 536924 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Birman, E; Blouin, MJ; Carboni, JM; David, S; Dool, CJ; Gottardis, M; Mashhedi, H; Pollak, M; Zakikhani, M; Zhao, Y	1

Other Studies

1 other study(ies) available for alloxan and bms 536924

Article	Year
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-related cancer, 2011, Volume: 18, Issue:6 Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Metformin; Protein Kinase Inhibitors; Pyridones; Receptor, IGF Type 1; Treatment Outcome	2011

Article

Year

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

Endocrine-related cancer, 2011, Volume: 18, Issue:6

Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Metformin; Protein Kinase Inhibitors; Pyridones; Receptor, IGF Type 1; Treatment Outcome

2011